Document Detail


Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial.
MedLine Citation:
PMID:  10371089     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Specific immunotherapy (SIT) is a valuable treatment for respiratory allergy, and the use of chemically modified allergens (allergoids) has improved its safety, as testified by several studies. We evaluated the effects of a SIT course with an allergoid extract of Parietaria pollen in a double-blind, placebo-controlled trial. METHODS: The study was double-blind in the first year; then it was prolonged up to 3 years with all patients on active treatment. Clinical effectiveness, safety, skin reactivity, systemic immunologic parameters, and subjective assessment were evaluated. We also had available a self-evaluation recorded in a follow-up visit 4 years after the discontinuation of SIT. RESULTS: A significant reduction of the symptoms plus drug intake scores during the pollen seasons was observed in the patients receiving active SIT. The placebo patients, after switching to active SIT, also showed significant clinical improvement. The clinical efficacy persisted during years 2 and 3 of treatment. After year 1, the actively treated patients reported a significant subjective improvement (frequency of symptoms, P = 0.001; duration of symptoms, P = 0.024; physical performance, P = 0.043) compared with the placebo group. The self-evaluation by visual analog scale showed that all patients maintained a significant clinical improvement up to 4 years after discontinuing SIT (year 1: active=+31.6%, placebo=-15.7%; year 7: active=+35.8%, placebo=+31.3%). The systemic immunologic changes after active SIT paralleled those described elsewhere (IgE decreased from 22 to 9 and from 21 to 8 IU/ml; IgG4 increased from 43 to 87 and from 18 to 60 IU/ml). A significant decrease in skin reactivity to three different allergen concentrations was observed at year 3 compared with pretreatment values (P<0.05). CONCLUSIONS: The investigational SIT with Parietaria appeared to be effective and safe; a 3-year course of treatment achieved a long-lasting efficacy.
Authors:
R Ariano; A M Kroon; G Augeri; G W Canonica; G Passalacqua
Related Documents :
10971859 - Preventive symptomatic immunotherapy versus placebo in seasonal rhinitis due to grasses...
20864799 - Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis ...
2443539 - Effect of short-term systemic glucocorticoid treatment on human nasal mediator release ...
9314339 - A double-blind study of the discontinuation of ragweed immunotherapy.
20109319 - Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal s...
16466599 - A double blind, placebo controlled trial of inert cellulose powder for the relief of sy...
9519099 - Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. ...
18221629 - The role of depression in the etiology of acute coronary syndrome.
18319599 - Depressive symptoms, vascular risk factors and mild cognitive impairment. the italian l...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Allergy     Volume:  54     ISSN:  0105-4538     ISO Abbreviation:  Allergy     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-09-02     Completed Date:  1999-09-02     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7804028     Medline TA:  Allergy     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  313-9     Citation Subset:  IM    
Affiliation:
Servizio di Allergologia, Ospedale di Bordighera (IM), Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Asthma / therapy
Conjunctivitis, Allergic / therapy*
Desensitization, Immunologic*
Double-Blind Method
Female
Humans
Male
Middle Aged
Plant Extracts / immunology*
Pollen / immunology*
Rhinitis, Allergic, Perennial / therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Allergoid; 0/Plant Extracts

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness--a mur...
Next Document:  Association of ambient air-pollution levels with acute asthma exacerbation among children in Singapo...